Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? (Q38107793)

29 August 2017

title

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? (English)

1 reference

29 August 2017

main subject

angiogenesis inhibitor

1 reference

1 reference

Alberto Bardelli

2

0 references

author name string

Alessia Bottos

series ordinal

1

1 reference

29 August 2017

publication date

18 May 2013

1 reference

Cellular and Molecular Life Sciences

29 August 2017

published in

1 reference

29 August 2017

volume

70

1 reference

29 August 2017

issue

21

1 reference

29 August 2017

page(s)

4131-4140

1 reference

Mechanisms of angiogenesis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Openings between defective endothelial cells explain tumor vessel leakiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

FDA accelerated approval benefits glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Heterogeneous vascular dependence of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Glioblastoma stem-like cells give rise to tumour endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Stromal fibroblasts in cancer: a novel tumor-promoting cell type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b Gr1 myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

MAP kinases and hypoxia in the control of VEGF expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Targets of Raf in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Impact of oncogenes in tumor angiogenesis: Mutant K- ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumor vascular changes mediated by inhibition of oncogenic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Anti-angiogenesis therapy in cancer: Current challenges and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Contribution of bone marrow–derived endothelial cells to human tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00018-013-1331-3

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

21 January 2018

1 reference

12 December 2020

Stimulation of angiogenesis by Ras proteins

1 reference

12 December 2020

The role of cancer stem cells in relapse of solid tumors

1 reference

12 December 2020

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

1 reference

12 December 2020

Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121

1 reference

12 December 2020

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

12 December 2020

Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma

1 reference

12 December 2020

Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis

1 reference

12 December 2020

Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells

1 reference

12 December 2020

Targeted therapies: bevacizumab--has it reached its final resting place?

1 reference

12 December 2020

Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.

1 reference

12 December 2020

Vascular permeability factor, an endothelial cell mitogen related to PDGF

1 reference

12 December 2020

Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination

1 reference

12 December 2020

Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

1 reference

12 December 2020

Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines

1 reference

12 December 2020

The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers

1 reference

12 December 2020

10.1007/S00018-013-1331-3

Identifiers

DOI

1 reference

29 August 2017

1 reference